CancerLunan Pharmaceutical patents new RET inhibitorsLunan Pharmaceutical Group Corp. has detailed proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) inhibitors and/or its mutants found to be potentially useful for the treatment of cancer.